Characterization of new and advancement of existing animal models of bacillus anthracis infection

Biodefense Research Methodology and Animal Models, Second Edition

Volumn , Issue , 2012, Pages 81-98

  Leffel, Elizabeth K ^a   Pitt, M Louise M ^b  

^a PharmAthene Inc   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879390646     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b11523     Document Type: Chapter

References (126)

1. Hambleton, P., J.A. Carman, and J. Melling, Anthrax: The disease in relation to vaccines. Vaccine, 1984, 2(2): 125-132.
2. Jager, H.G., H.H. Booker, and O.J. Hubschle, Anthrax in cheetahs (Acinonyx jubatus) in Namibia. J Wildl Dis, 1990, 26(3): 423-424.
3. Mayer, T.A. et al., Clinical presentation of inhalational anthrax following bioterrorism exposure: Report of 2 surviving patients. JAMA, 2001, 286(20): 2549-2553.
4. Jernigan, D.B. et al., Investigation of bioterrorism-related anthrax, United States, 2001: Epidemiologic findings. Emerg Infect Dis, 2002, 8(10): 1019-1028.
5. Albrink, W.S., Pathogenesis of inhalation anthrax. Bacteriol Rev, 1961, 25: 268-273.
6. Brachman, P.S., Inhalation anthrax. Ann N Y Acad Sci, 1980, 353: 83-93.
7. Friedlander, A.M., Anthrax: Clinical features, pathogenesis, and potential biological warfare threat. Curr Clin Top Infect Dis, 2000, 20: 335-349.
8. Hail, A.S. et al., Comparison of noninvasive sampling sites for early detection of Bacillus anthracis spores from rhesus monkeys after aerosol exposure. Mil Med, 1999, 164(12): 833-837.
9. Lew, D., Bacillus anthracis (anthrax), in Principles and Practices of Infectious Disease, G. Mandell, J. Bennett, and D. R., editors. New York: Churchill Livingstone Inc., 1995, pp. 1885-1889.
10. Tekin, A., N. Bulut, and T. Unal, Acute abdomen due to anthrax. Br J Surg, 1997, 84(6): 813.
11. Inglesby, T.V. et al., Anthrax as a biological weapon: Medical and public health management. Working Group on Civilian Biodefense. JAMA, 1999, 281(18): 1735-1745.
12. Friedlander, A.M., Anthrax, in Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. Washington, DC: Office of the Surgeon General at TMM Publications, 1997, p. 467.
13. Zilinskas, R.A., Iraq’s biological weapons. The past as future? JAMA, 1997, 278(5): 418-424.
14. Doolan, D.L. et al., The US capitol bioterrorism anthrax exposures: Clinical epidemiological and immunological characteristics. J Infect Dis, 2007, 195(2): 174-184.
15. Becker, C., 20/20 Hindsight. Months after anthrax claimed the lives of several Americans, hospitals review their reaction to the event-and plan for future crises. Mod Healthc, 2002, 32(8): 8-9, 12.
16. Doganay, M. and G. Metan, Human anthrax in Turkey from 1990 to 2007. Vector Borne Zoonotic Dis, 2009, 9(2): 131-140.
17. Beaumont, G., Anthrax in a Scottish intravenous drug user. J Forensic Leg Med, 2010, 17(8): 443-445.
18. Abalakin, V.A. and B.L. Cherkasskii, Use of inbred mice as a model for the indication and differentiation of Bacillus anthracis strains (in Russian). Zh Mikrobiol Epidemiol Immunobiol, 1978(2): 146-147.
19. Welkos, S.L., T.J. Keener, and P.H. Gibbs, Differences in susceptibility of inbred mice to Bacillus anthracis. Infect Immun, 1986, 51(3): 795-800.
20. Welkos, S.L. and A.M. Friedlander, Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb Pathog, 1988, 4(1): 53-69.
21. Shibaya, M., M. Kubomichi, and T. Watanabe, The genetic basis of host resistance to Bacillus anthracis in inbred mice. Vet Microbiol, 1991, 26(3): 309-312.
22. Welkos, S. et al., The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology, 2001, 147(Pt 6): 1677-1685.
23. Welkos, S.L., N.J. Vietri, and P.H. Gibbs, Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence. Microb Pathog, 1993, 14(5): 381-388.
24. Lyons, C.R. et al., Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility. Infect Immun, 2004, 72(8): 4801-4809.
25. Heine, H.S. et al., Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model. Antimicrob Agents Chemother, 2007, 51(4): 1373-1379.
26. Glomski, I.J. et al., Inhaled non-capsulated Bacillus anthracis in A/J mice: Nasopharynx and alveolar space as dual portals of entry, delayed dissemination, and specific organ targeting. Microbes Infect, 2008, 10(12-13): 1398-1404.
27. Glomski, I.J. et al., Noncapsulated toxinogenic Bacillus anthracis presents a specific growth and dissemination pattern in naive and protective antigen-immune mice. Infect Immun, 2007, 75(10): 4754-4761.
28. Loving, C.L. et al., Murine aerosol challenge model of anthrax. Infect Immun, 2007, 75(6): 2689-2698.
29. Duong, S., L. Chiaraviglio, and J.E. Kirby, Histopathology in a murine model of anthrax. Int J Exp Pathol, 2006, 87(2): 131-137.
30. Flick-Smith, H.C. et al., Mouse model characterisation for anthrax vaccine development: Comparison of one inbred and one outbred mouse strain. Microb Pathog, 2005, 38(1): 33-40.
31. Chabot, D.J. et al., Anthrax capsule vaccine protects against experimental infection. Vaccine, 2004, 23(1): 43-47.
32. Heine, H.S. et al., Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. Antimicrob Agents Chemother, 2008, 52(9): 3350-3357.
33. Drysdale, M. et al., Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax. EMBO J, 2005, 24(1): 221-227.
34. Pickering, A.K. et al., Cytokine response to infection with Bacillus anthracis spores. Infect Immun, 2004, 72(11): 6382-6389.
35. Pickering, A.K. and T.J. Merkel, Macrophages release tumor necrosis factor alpha and interleukin-12 in response to intracellular Bacillus anthracis spores. Infect Immun, 2004, 72(5): 3069-3072.
36. Steward, J. et al., Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones. J Antimicrob Chemother, 2004, 54(1): 95-99.
37. Chand, H.S. et al., Discriminating virulence mechanisms among Bacillus anthracis strains by using a murine subcutaneous infection model. Infect Immun, 2009, 77(1): 429-435.
38. Cote, C.K., N. Van Rooijen, and S.L. Welkos, Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection. Infect Immun, 2006, 74(1): 469-480.
39. Drysdale, M. et al., Murine innate immune response to virulent toxigenic and nontoxigenic Bacillus anthracis strains. Infect Immun, 2007, 75(4): 1757-1764.
40. Lincoln, R.E., Advances in Veterinary Science. New York: Academic Press, 1964.
41. Jones, W.I., Jr. et al., In vivo growth and distribution of anthrax bacilli in resistant, susceptible, and immunized hosts. J Bacteriol, 1967, 94(3): 600-608.
42. Beall, F.A., M.J. Taylor, and C.B. Thorne, Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J Bacteriol, 1962, 83: 1274-1280.
43. Beall, F.A. and F.G. Dalldorf, The pathogenesis of the lethal effect of anthrax toxin in the rat. J Infect Dis, 1966, 116(3): 377-389.
44. Haines, B.W., F. Klein, and R.E. Lincoln, Quantitative assay for crude anthrax toxins. J Bacteriol, 1965, 89: 74-83.
45. Fish, D.C. et al., Pathophysiological changes in the rat associated with anthrax toxin. J Infect Dis, 1968, 118(1): 114-124.
46. Mourez, M. et al., Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis. Proc Natl Acad Sci USA, 2003, 100(24): 13803-13808.
47. Sarac, M.S. et al., Protection against anthrax toxemia by hexa-d-arginine in vitro and in vivo. Infect Immun, 2004, 72(1): 602-605.
48. Sawada-Hirai, R. et al., Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines, 2004, 2(1): 5.
49. Webster, J.I., M. Moayeri, and E.M. Sternberg, Novel repression of the glucocorticoid receptor by anthrax lethal toxin. Ann N Y Acad Sci, 2004, 1024: 9-23.
50. Ivins, B.E. et al., Immunization studies with attenuated strains of Bacillus anthracis. Infect Immun, 1986, 52(2): 454-458.
51. Turnbull, P.C. et al., Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun, 1986, 52(2): 356-363.
52. Ivins, B.E. et al., Transposon Tn916 mutagenesis in Bacillus anthracis. Infect Immun, 1988, 56(1): 176-181.
53. Ivins, B.E. et al., Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect Immun, 1990, 58(2): 303-308.
54. Ivins, B.E. et al., Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect Immun, 1992, 60(2): 662-668.
55. Little, S.F. and G.B. Knudson, Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect Immun, 1986, 52(2): 509-512.
56. Ross, J.M., On the histopathology of experimental anthrax in the guinea-pig. Br J Exp Pathol, 1955, 36(3): 336-339.
57. Ross, J.M., The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol, 1957, 73: 485-495.
58. Puziss, M. and G.G. Wright, Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man. J Bacteriol, 1963, 85: 230-236.
59. Ivins, B.E. and S.L. Welkos, Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis. Infect Immun, 1986, 54(2): 537-542.
60. Ivins, B.E. and S.L. Welkos, Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol, 1988, 4(1): 12-19.
61. Lincoln, R.E. et al., Value of field data for extrapolation in anthrax. Fed Proc, 1967, 26(5): 1558-1562.
62. Benjamin, E. et al., LD50 of aerosolized B. anthracis and deposition of spores in the Hartley guinea pig, in ASM Biodefense Research Meeting, 2005, Baltimore, MD, USA. p. Abstract # 96(R).
63. Ivins, B. et al., Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine, 1995, 13(18): 1779-1784.
64. Altboum, Z. et al., Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect Immun, 2002, 70(11): 6231-6241.
65. Little, S.F. et al., Development of an in vitro-based potency assay for anthrax vaccine. Vaccine, 2004, 22(21-22): 2843-2852.
66. Kobiler, D. et al., Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect Immun, 2002, 70(2): 544-560.
67. Barnes, J.M., The development of anthrax following the administration of spore by inhalation. Br J Exp Pathol, 1947, 28: 385-394.
68. Dalldorf, F.G. and F.A. Beall, Capillary thrombosis as a cause of death in experimental anthrax. Arch Pathol, 1967, 83(2): 154-161.
69. Fasanella, A. et al., Detection of anthrax vaccine virulence factors by polymerase chain reaction. Vaccine, 2001, 19(30): 4214-4218.
70. Kolesnik, V.S. et al., Experimental anthrax infection in laboratory animals with differing species susceptibility to the causative agent (in Russian). Zh Mikrobiol Epidemiol Immunobiol, 1990(6): 3-7.
71. Terril, L. and D. Clemons, The Laboratory Guinea Pig. Boca Raton: CRC Press, 1998.
72. Fellows, P.F. et al., Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine, 2001, 19(23-24): 3241-3247.
73. Gauthier, Y.P. et al., Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax. Infect Immun, 2009, 77(3): 1197-1207.
74. Little, S.F. et al., Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun, 1997, 65(12): 5171-5175.
75. Mabry, R. et al., Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect Immun, 2005, 73(12): 8362-8368.
76. Reuveny, S. et al., Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun, 2001, 69(5): 2888-2893.
77. Hambleton, P. and P.C. Turnbull, Anthrax vaccine development: A continuing story. Adv Biotechnol Processes, 1990, 13: 105-122.
78. Marcus, H. et al., Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine. Infect Immun, 2004, 72(6): 3471-3477.
79. Pitt, M.L. et al., In vitro correlate of immunity in an animal model of inhalational anthrax. J Appl Microbiol, 1999, 87(2): 304.
80. Ionin, B., Development of a guinea pig model for post-exposure prophylaxis of inhalation anthrax, in Biodefense Vaccines & Therapeutics Conference-Animal Models Forum, June 15, 2010, Washington, D.C.
81. Richter, S. et al., Capsule anchoring in Bacillus anthracis occurs by a transpeptidation reaction that is inhibited by capsidin. Mol Microbiol, 2009, 71(2): 404-420.
82. Peterson, J.W. et al., Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun, 2006, 74(2): 1016-1024.
83. Zaucha, G.M. et al., The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med, 1998, 122(11): 982-992.
84. Nordberg, B.K., C.G. Schmiterlow, and H.J. Hansen, Pathophysiological investigations into the terminal course of experimental anthrax in the rabbit. Acta Pathol Microbiol Scand, 1961, 53: 295-318.
85. Klein, F. et al., Pathophysiology of anthrax. J Infect Dis, 1966, 116(2): 123-138.
86. Lebowich, R.J., B.G. McKillip, and J.R. Convoy, Cutaneous anthrax-A pathologic study with clinical correlation. Am J Clin Pathol, 1943, 13: 505-515.
87. Aleksandrov, N.I. et al., Further experimental study of the efficacy of chemical anthrax vaccine (in Russian). Zh Mikrobiol Epidemiol Immunobiol, 1964, 41: 45-50.
88. Pitt, M.L. et al., In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine, 2001, 19(32): 4768-4773.
89. Galloway, D.R. and L. Baillie, DNA vaccines against anthrax. Expert Opin Biol Ther, 2004, 4(10): 1661-1667.
90. Little, S.F. et al., Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine, 2006, 24(14): 2530-2536.
91. Mikszta, J.A. et al., Protective immunization against inhalational anthrax: A comparison of minimally invasive delivery platforms. J Infect Dis, 2005, 191(2): 278-288.
92. Little, S.F. et al., Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine, 2004, 22(3-4): 422-430.
93. Weiss, S. et al., Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect Immun, 2006, 74(1): 394-398.
94. Nuzum, E. National Institute for Allergic and Infectious Diseases (NIAID) studies, in FDA Vaccines and Related Biological Products Advisory Committee, Maryland, USA, 2010.
95. Mohamed, N. et al., A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun, 2005, 73(2): 795-802.
96. Thomas, L.J. et al., Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice. Hum Vaccin, 2009, 5(2): 79-84.
97. Migone, T.S. et al., Raxibacumab for the treatment of inhalational anthrax. N Engl J Med, 2009, 361(2): 135-144.
98. Rossi, C.A. et al., Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax. Infect Immun, 2008, 76(12): 5790-5801.
99. Yee, S. et al., Aerosolized Bacillus anthracis infection in New Zealand white rabbits: Natural history and intravenous levofloxacin treatment. Comp Med, 2010, 60(6): 461-468.
100. Albrink, W.S. and R.J. Goodlow, Experimental inhalation anthrax in the chimpanzee. Am J Pathol, 1959, 35: 1055-1065.
101. Klein, F. et al., Anthrax toxin: Causative agent in the death of rhesus monkeys. Science, 1962, 138: 1331-1333.
102. Kelly, D.J. et al., Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys. J Infect Dis, 1992, 166(5): 1184-1187.
103. Fritz, D.L. et al., Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest, 1995, 73(5): 691-702.
104. Ivins, B.E. et al., Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine, 1998, 16(11-12): 1141-1148.
105. Kihira, T., J. Sato, and T. Shibata, Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis. J Infect Chemother, 2004, 10(2): 97-100.
106. Klinman, D.M. et al., CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine, 2004, 22(21-22): 2881-2886.
107. Vasconcelos, D. et al., Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab Invest, 2003, 83(8): 1201-1209.
108. Twenhafel, N.A., E. Leffel, and M.L. Pitt, Pathology of inhalational anthrax infection in the African green monkey. Vet Pathol, 2007, 44(5): 716-721.
109. Lever, M.S. et al., Experimental respiratory anthrax infection in the common marmoset (Callithrix jacchus). Int J Exp Pathol, 2008, 89(3): 171-179.
110. Haas, C.N., On the risk of mortality to primates exposed to anthrax spores. Risk Anal, 2002, 22(2): 189-193.
111. Borio, L. et al., Death due to bioterrorism-related inhalational anthrax: Report of 2 patients. JAMA, 2001, 286(20): 2554-2559.
112. Grinberg, L.M. et al., Quantitative pathology of inhalational anthrax I: Quantitative microscopic findings. Mod Pathol, 2001, 14(5): 482-495.
113. Gleiser, C.A., Pathology of anthrax infection in animal hosts. Fed Proc, 1967, 26(5): 1518-1521.
114. Guarner, J. et al., Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol, 2003, 163(2): 701-709.
115. Berdjis, C.C. et al., Pathogenesis of respiratory anthrax in Macaca mulatta. Br J Exp Pathol, 1962, 43: 515-524.
116. Gleiser, C.A. et al., Pathology of experimental respiratory anthrax in Macaca mulatta. Br J Exp Pathol, 1963, 44: 416-426.
117. Ivins, B.E., P.F. Fellows, and G.O. Nelson, Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs. Vaccine, 1994, 12(10): 872-874.
118. Blasky, A.J. et al., Rapid high-resolution MHC class I genotyping of Chinese rhesus macaques by capillary reference strand-mediated conformational analysis. Immunogenetics, 2008, 60(10): 575-584.
119. Karl, J.A. et al., Identification of MHC class I sequences in Chinese-origin rhesus macaques. Immunogenetics, 2008, 60(1): 37-46.
120. Vietri, N.J. et al., Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci USA, 2006, 103(20): 7813-7816.
121. Vietri, N.J. et al., A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics. J Infect Dis, 2009, 199(3): 336-341.
122. Gill, J.R. and J. Melinek, Inhalation of anthrax: Gross autopsy findings. Arch Pathol Lab Med, 2002, 126(8): 993-994.
123. Dyer, D. et al., Development of a therapeutic African green monkey model for inhalational anthrax to demonstrate added value of adjunct therapies, in Bacillus-ACT 2009: The International Bacillus anthracis, B. cereus, and B. thuringiensis Conference, New Mexico, USA, 2009.
124. Vitale, L. et al., Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun, 2006, 74(10): 5840-5847.
125. Whipple, E.C. et al., Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys. Mol Immunol, 2007, 44(4): 377-388.
126. Stearns-Kurosawa, D.J. et al., Sepsis and pathophysiology of anthrax in a nonhuman primate model. Am J Pathol, 2006, 169(2): 433-444.